The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Will fund a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years.

Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Spanish plasma-based medicines maker Grifols (MCE: GRF) has announced disappointing top-line data from its Phase III PRECIOSA clinical trial evaluating the potential of long-term albumin treatment ...

US short seller Gotham City Research asked a judge in New York to dismiss a lawsuit accusing it of conspiring to drive down shares in Grifols SA. The drug maker’s market capitalization has ...

US short seller Gotham City Research asked a judge in New York to dismiss a lawsuit accusing it of conspiring to drive down shares in Grifols SA. The drug maker’s market capitalization has fallen by ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(Bloomberg) -- Grifols SA has included a term in its €1.3 billion ($1.4 billion) private debt placement that would allow Brookfield Asset Management Ltd. to refinance the deal early — a sign ...